Correction: Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis - Shuo Yang; Yibing Hou; Xiaohui Wang; Shuo Kang; Zhenhua Pan (PLoS ONE, 2026)